A Phase 1b/2 Study of the Oral CDK4/6 Inhibitor LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in Metastatic Castration Resistant Prostate Cancer
Phase of Trial: Phase I/II
Latest Information Update: 12 Jun 2017
At a glance
- Drugs Docetaxel (Primary) ; Prednisone (Primary) ; Ribociclib (Primary) ; Filgrastim
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 06 Jun 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 06 Jun 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.